ASX:IPD ImpediMed (IPD) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About ImpediMed Stock (ASX:IPD) 30 days 90 days 365 days Advanced Chart Remove Ads Get ImpediMed alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume1.62 million shsAverage VolumeN/AMarket Capitalization$103.31 millionP/E RatioN/ADividend Yield3.28%Price TargetN/AConsensus RatingN/A Company OverviewImpediMed Limited, a medical technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) devices and software services in Australia, North America, and internationally. The company offers SOZO, a noninvasive BIS device for the assessment of lymphedema, and deliver snapshot of fluid status and tissue composition; SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications. It sells its devices to hospitals and clinics. The company was incorporated in 1999 and is headquartered in Pinkenba, Australia.Read More… Remove Ads Receive IPD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ImpediMed and its competitors with MarketBeat's FREE daily newsletter. Email Address IPD Stock News Headlines“Accelerate Action” to boost women’s leadership in Aussie healthcare sectorMarch 7, 2025 | msn.comHealth Check: Percheron ‘closes the book’ on failed childhood rare disease programFebruary 6, 2025 | msn.com“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.April 4, 2025 | Weiss Ratings (Ad)ImpediMed Secures $15M Growth Capital to Drive ExpansionFebruary 5, 2025 | tipranks.comImpediMed (ASX:IPD) investors are sitting on a loss of 72% if they invested three years agoFebruary 5, 2025 | finance.yahoo.comImpediMed Limited Reports Director’s Share AcquisitionJanuary 31, 2025 | tipranks.comImpediMed Leads Our Trio Of ASX Penny Stock HighlightsJanuary 9, 2025 | finance.yahoo.comImpediMed Limited Increases Director’s ShareholdingDecember 25, 2024 | markets.businessinsider.comSee More Headlines IPD Stock Analysis - Frequently Asked Questions What other stocks do shareholders of ImpediMed own? Based on aggregate information from My MarketBeat watchlists, some other companies that ImpediMed investors own include Bardoc Gold (BDC) and Appen (APX). Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Medical Devices Sub-IndustryN/A Current SymbolASX:IPD CIKN/A Webwww.impedimed.com Phone61 7 3860 3700FaxN/AEmployees76Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E Growth-102.5Net Income$-19,790,000.00 Net Margins-191.78% Pretax MarginN/A Return on Equity-43.15% Return on Assets-25.96% Debt Debt-to-Equity Ratio2.81 Current Ratio6.33 Quick Ratio6.23 Sales & Book Value Annual Sales$10.32 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow1.60 Book ValueA$0.02 per share Price / BookN/AMiscellaneous Outstanding Shares2,020,000,000Free FloatN/AMarket Cap$103.31 million OptionableNot Optionable Beta2.86 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (ASX:IPD) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImpediMed Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share ImpediMed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.